Literature DB >> 16362636

Neuroprotection of cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window.

E Schauer1, R Wronski, J Patockova, H Moessler, E Doppler, B Hutter-Paier, M Windisch.   

Abstract

All attempts to reduce neuronal damage after acute brain ischemia by the use of neuroprotective compounds have failed to prove efficacy in clinical trials so far. One of the main reasons might be the relatively narrow time window for intervention. In this study 2 different tissue culture models of ischemia, excitotoxic lesion by the use of glutamate and oxygen-glucose deprivation (OGD), were used to investigate the effects of delayed application of Cerebrolysin (Cere) on neuronal survival. This drug consists of low molecular weight peptides with neuroprotective and neurotrophic properties similar to naturally occurring growth factors. After both types of lesion, acute as well as delayed treatment with Cere resulted in a dose dependent and significant rescue of neurons. In the model of excitotoxic cell death significant drug effects were found even when the treatment started with a delay of 96 hours after addition of glutamate. In the OGD model pronounced effects were found after 48 hours delay of treatment, and even after 72 hours a small but significant rescue of neurons was detected. The neuroprotective effects of a single addition of Cerebrolysin to the culture medium resulted in significant protection until end of the experiments which was up to 2 weeks after the initial lesion. A shift of the efficacious dosages from low to high concentrations indicates that most likely active compounds are used up, indicating that multiple dosing might even increase the effect size. In conclusion the results indicate that Cere displays a relatively wide therapeutic time window which might be explained by a combination of acute neuroprotective properties and neurotrophic efficacy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16362636     DOI: 10.1007/s00702-005-0384-3

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  77 in total

Review 1.  Novel targets for therapeutic intervention against ischemic brain injury.

Authors:  A Sun; J Cheng
Journal:  Clin Neuropharmacol       Date:  1999 May-Jun       Impact factor: 1.592

2.  delta-, but not mu- and kappa-, opioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury.

Authors:  J Zhang; G G Haddad; Y Xia
Journal:  Brain Res       Date:  2000-12-08       Impact factor: 3.252

3.  Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons.

Authors:  M Hartbauer; B Hutter-Paier; G Skofitsch; M Windisch
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

Review 4.  The problem of assessing effective neuroprotection in experimental cerebral ischemia.

Authors:  D Corbett; S Nurse
Journal:  Prog Neurobiol       Date:  1998-04       Impact factor: 11.685

5.  Brain-derived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat.

Authors:  I Ferrer; J Krupinski; E Goutan; E Martí; S Ambrosio; E Arenas
Journal:  Acta Neuropathol       Date:  2001-03       Impact factor: 17.088

6.  Antagonism of non-NMDA receptors augments the neuroprotective effect of NMDA receptor blockade in cortical cultures subjected to prolonged deprivation of oxygen and glucose.

Authors:  D A Kaku; M P Goldberg; D W Choi
Journal:  Brain Res       Date:  1991-07-19       Impact factor: 3.252

Review 7.  The natural course of lesion development in brain ischemia.

Authors:  T Back; O G Schüler
Journal:  Acta Neurochir Suppl       Date:  2004

Review 8.  Neurotrophic activities and therapeutic experience with a brain derived peptide preparation.

Authors:  M Windisch; A Gschanes; B Hutter-Paier
Journal:  J Neural Transm Suppl       Date:  1998

9.  Delayed protection by MK-801 and tetrodotoxin in a rat organotypic hippocampal culture model of ischemia.

Authors:  J J Vornov; R C Tasker; J T Coyle
Journal:  Stroke       Date:  1994-02       Impact factor: 7.914

10.  Hypoxic cell death in human NT2-N neurons: involvement of NMDA and non-NMDA glutamate receptors.

Authors:  T Rootwelt; M Dunn; M Yudkoff; T Itoh; R Almaas; D Pleasure
Journal:  J Neurochem       Date:  1998-10       Impact factor: 5.372

View more
  7 in total

1.  Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery.

Authors:  Dragos Catalin Jianu; Dafin Fior Muresanu; Ovidiu Bajenaru; Bogdan Ovidiu Popescu; Sanda Maria Deme; Herbert Moessler; Sibilla Zimmermann Meinzingen; Ligia Petrica; Ligia Petria
Journal:  J Med Life       Date:  2010 Jul-Sep

2.  Cerebrolysin for acute ischaemic stroke.

Authors:  Liliya Eugenevna Ziganshina; Tatyana Abakumova; Charles Hv Hoyle
Journal:  Cochrane Database Syst Rev       Date:  2020-07-14

3.  Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke.

Authors:  Mohammad Reza Amiri-Nikpour; Surena Nazarbaghi; Babak Ahmadi-Salmasi; Tayebeh Mokari; Urya Tahamtan; Yousef Rezaei
Journal:  Neuropsychiatr Dis Treat       Date:  2014-12-03       Impact factor: 2.570

Review 4.  Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Danfeng Zhang; Yan Dong; Ya Li; Jigang Chen; Junyu Wang; Lijun Hou
Journal:  Biomed Res Int       Date:  2017-06-05       Impact factor: 3.411

Review 5.  Cerebrolysin for acute ischaemic stroke.

Authors:  Liliya Eugenevna Ziganshina; Tatyana Abakumova; Ludivine Vernay
Journal:  Cochrane Database Syst Rev       Date:  2016-12-05

6.  Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial.

Authors:  Sahar M A Hassanein; Shaymaa M Deifalla; Moustafa El-Houssinie; Somaia A Mokbel
Journal:  J Clin Neurol       Date:  2015-09-11       Impact factor: 3.077

7.  Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Peter Y M Woo; Joanna W K Ho; Natalie M W Ko; Ronald P T Li; Leo Jian; Alberto C H Chu; Marco C L Kwan; Yung Chan; Alain K S Wong; Hoi-Tung Wong; Kwong-Yau Chan; John C K Kwok
Journal:  BMC Neurol       Date:  2020-11-03       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.